AstraZeneca to cut some direct-to-patient US drug prices after Trump demand

Core Viewpoint - AstraZeneca will sell its diabetes and asthma drugs directly to cash-paying U.S. patients at discounts of up to 70% off list prices, responding to increasing pressure in the pharmaceutical industry [1] Group 1 - The initiative reflects a growing trend among pharmaceutical companies to offer direct discounts to patients [1] - This move is part of AstraZeneca's strategy to enhance accessibility and affordability of essential medications [1] - The decision comes amid ongoing discussions about drug pricing and the need for more transparent pricing models in the healthcare sector [1]